Three months after settling a highly publicized fight with Virginia officials over whether he could refuse conventional medical treatment, Starchild Abraham Cherrix appears to be making major progress.
"I feel amazing. I'm just a ball of fire now," Cherrix said en route to their home on Virginia's Eastern Shore. They had spent the past six weeks in Mississippi, where Cherrix was treated by a new oncologist for Hodgkin's disease.
More in this article in the Washington Post today.
Comment: cases like these point to the fact that all patients are entitled to and should seek a second or third opinion on their diagnosis and treatment if they so desire. For many lymphomas, there are multiple conventional treatments available but some doctors may be hesitent to use a non-current protocol because it is older or very new. Radiation alone can work on some lymphomas but may be discounted because of long-term side effects, etc.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...